Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.
Pamela L. Kunz
Advertisement
Articles by Pamela L. Kunz
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.
Advertisement
Latest Updated Articles
Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine TumorsPublished: January 16th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5